Scienza e Tecnologia
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Thursday, March 3, 2022
5:00 p.m. Eastern Standard Time
(888) 664-6383
(416) 764-8650
(if needed) 4650-7590
please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 ( North America ) or (416) 764-8677 (International) and using replay code: 507-590#.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
Director of IR & Communication
+1-858-886-7813
jpatton@oncolytics.ca
LifeSci Advisors
+1-917-679-9282
tim@lifesciadvisors.com
Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg